Last week, fellow patients from more than two dozen U.S. states co-signed a letter with me to welcome the newly appointed (and confirmed!) Commissioner of the Food & Drug Administration (FDA). 

This is a huge deal for us patients! The letter, which can be found here, formally congratulates and welcomes the Commissioner, and, as importantly, shares our willingness to help the FDA as it continues its important work protecting patients, accelerating the approval of new and innovative medicines such as biosimilars, and addresses the epidemic of opioid addiction. 

The reason we’re so excited to welcome Dr. Califf, who is a cardiologist originally from Duke University (and formerly the head of Duke’s Clinical Trial program) is because he’s so patient-centered and so patient-friendly. This isn’t to say that past Commissioners haven’t been, but with Dr. Califf’s appointment the role of the patient is now elevated and hopefully the perspective of the patient will be further integrated into decisions made by this important regulatory body. 

I also had the chance to get to know Dr. Califf personally as his involvement with PCORnet afforded us several opportunities to speak with one another. 

Given his familiarity with the Patient Powered Research Network ArthritisPower, and the role he played in helping shape this National Resource as it was developed, we are eager to work more closely with FDA and others to provide the patient perspective in all relevant areas. 

In the future, if you’d like to join us in co-signing these important letters, or for more information about similar initiatives, see and

To Good Health!